Clenbuterol — Dosing, Cycles, Half-Life & Side Effects

Clenbuterol is a β₂-adrenergic agonist with a half-life of ~35 hours in healthy adult humans (Yamamoto et al. 1985, J Pharmacobiodyn, PMID: 4045696, oral 20-80 mcg). Earlier 36-48h estimates appear to have conflated with non-human data (rabbits ~9h, rats ~30h in the same study).. Beta-2 adrenergic agonist for fat loss and bronchodilation. This page is educational harm-reduction reference compiled from peer-reviewed literature — not medical advice, not an endorsement, not a recommendation to use. Consult a licensed clinician before any decision.

Quick Facts

ClassBeta-2 Agonist
Half-life~35 hours in healthy adult humans (Yamamoto et al. 1985, J Pharmacobiodyn, PMID: 4045696, oral 20-80 mcg). Earlier 36-48h estimates appear to have conflated with non-human data (rabbits ~9h, rats ~30h in the same study).
Elimination half-life (free hormone)~35 hours (oral, healthy human volunteers; Yamamoto, Iwata, Nakashima 1985)
Detection window10 days
HepatotoxicityLow
Suppression0/10
Administrationoral
US regulatory statusnot-approved

Typical Dosing Ranges

Common dose range: 20-100mcg/day male / 20-80mcg/day female (Wave B.1 ceiling reduction, audit-driven 2026-04-18, see warnings + citations for evidence basis).

Cycle length: 2-4 weeks

Time to steady state: ~7.5 days

Dose ranges are compiled from published pharmacokinetic studies and community-reported usage. Where a value is community-reported rather than clinically studied, this page and its structured data flag it. Lower end of any range is always the safer starting point.

Stacking Considerations

PCT Requirements

  • Depot clearance estimate: ~8 days post-last-dose before SERM start (5 × apparent depot half-life of 36h).
  • Never stack two SERMs. Extend a single SERM (tamoxifen OR enclomiphene/clomiphene) rather than combining.
  • Use the cycle planner to generate a full protocol based on your complete stack, not this compound alone.

Side Effect Profile

  • Tremors
  • Insomnia
  • Tolerance development
  • Cardiac stress

Known Interactions

  • Trenbolone Acetate + Clenbuterol

    major — cardiovascular

    Both significantly impact cardiovascular system. Trenbolone raises BP, clenbuterol stresses heart.

    Recommendation: Avoid combination. If used, monitor BP and heart rate closely.

    Monitor: Blood pressure, Heart rate, ECG

  • Ephedrine / ECA Stack + Clenbuterol

    major — cardiovascular

    Both are stimulants with significant cardiovascular effects.

    Recommendation: Never combine. Risk of cardiac events is significantly elevated.

    Monitor: Heart rate, Blood pressure, ECG

Related compounds

Monitoring (Bloodwork & Vitals)

  • Comprehensive metabolic panel (baseline, mid-cycle, post-cycle)
  • Lipid panel (total cholesterol, HDL, LDL, triglycerides)
  • CBC (hemoglobin, hematocrit — watch for erythrocytosis)
  • Sex-hormone panel (Total T, Free T, Estradiol sensitive, SHBG, LH, FSH)
  • Blood pressure (weekly self-check; flag systolic >140 or diastolic >90)

Baseline bloodwork is recommended before any cycle. Discontinue if liver enzymes exceed 3× upper limit of normal or if hematocrit exceeds 54%.

Frequently Asked Questions

What is the half-life of Clenbuterol?

Clenbuterol has a half-life of approximately ~35 hours in healthy adult humans (Yamamoto et al. 1985, J Pharmacobiodyn, PMID: 4045696, oral 20-80 mcg). Earlier 36-48h estimates appear to have conflated with non-human data (rabbits ~9h, rats ~30h in the same study).. Clearance estimate: 36h × 5 = 180h = 7.5 days. This figure is used to determine injection frequency (for esters) and post-cycle clearance timing.

What is the typical dose range for Clenbuterol?

Commonly reported ranges for Clenbuterol: 20-100mcg/day male / 20-80mcg/day female (Wave B.1 ceiling reduction, audit-driven 2026-04-18, see warnings + citations for evidence basis).. Cycle length: 2-4 weeks. These are compiled from published studies and community-reported usage — individual response varies and lower end is always preferred.

Does Clenbuterol suppress natural testosterone?

Clenbuterol causes minimal suppression of the HPTA axis (score 0/10). PCT may still be advisable depending on stack and duration.

Is Clenbuterol liver toxic?

Hepatotoxicity rating: Low. Non-17αα compound — liver stress is lower but still warrants periodic monitoring during a cycle.

What is Clenbuterol typically used for?

Clenbuterol is commonly used for: Fat loss, Performance enhancement, Intermediate users. Intended-use context does not imply safety — every use case carries the same underlying pharmacological risks.

Citations

  1. Yamamoto I, Iwata K, Nakashima M. 1985. J Pharmacobiodyn — Plasma terminal t½ ~35 h in healthy adult humans (oral 20, 40, 80 mcg). Same study reports ~30 h in rats and ~9 h in rabbits — interspecies variability appears to have driven the historical 36-48h range cited in some bodybuilding sources.
  2. FDA / WHO JECFA v38. 1992. WHO Food Additives Series 38 — Clenbuterol is NOT FDA-approved for human use in the US (approved as a veterinary bronchodilator in some countries; banned for food-animal use in many jurisdictions). regulatoryStatus: 'not-approved'.
  3. Kataveni S, Gourishetty RP, Mundada SM, Avvaru MP, Kollipara VS, Gottimukkala SP. 2025. Cureus — Documents cardiac events at the standard therapeutic dose (40 mcg/day): 'even standard or low doses of clenbuterol (40 μg/day) can cause serious adverse cardiac events.' Animal models: cardiac hypertrophy + collagen infiltration at 1.5-2 mg/kg in rodents. Cycle protocols (e.g., 2-on/2-off) do NOT prevent cumulative damage; β2-receptor desensitization defeats the anabolic claim. Reference for the 'no safe cardiac threshold' framing in the warnings block. PMC: PMC12200009
  4. Kumari S, Pal B, Sahu SK, Prabhakar PK, Tewari D. 2023. Int J Legal Med — Systematic review of 24 athletes with clenbuterol AEs across the dose range 20 mcg-30 mg. Cardiac complications were the MOST COMMON adverse-event category (SVT, AF, hypotension, chest pain, myocardial injury, myocarditis, myocardial ischemia, MI, cardiomyopathy). Death documented. Authors verbatim: 'Lack of evidence regarding the performance-enhancing effects of clenbuterol combined with its serious toxicities questions the usefulness of this drug in athletes.' No safe dose range recommended. Highest-quality human evidence available.
  5. Brett J, Dawson AH, Brown JA. 2014. Med J Aust — NSW Poisons Information Centre 5-year retrospective: 63 clenbuterol exposures, 84% (53/63) required hospitalization. One cardiac arrest in a 21-year-old man. Selection bias acknowledged (poisons-centre data over-represents overdose) but the high hospitalization rate is informative. Combined with Kataveni 2025 + Kumari 2023, justifies the Wave B.1 ceiling reduction from 140 → 100 mcg male / 100 → 80 mcg female.
  6. Kataveni S, Gourishetty RP, Mundada SM, Avvaru MP, Kollipara VS, Gottimukkala SP. Clenbuterol Abuse in Bodybuilding and Athletics: Unsupervised Use, Psychological Motivations, and Health Consequences. Cureus. 2025. PMC: PMC12200009
  7. Lopes PM, Albuquerque F, Ferreira AM, Trabulo M. Clenbuterol-induced myocarditis in a young man desiring to lose weight. BMJ Case Rep. 2022. PMID: 35288432
  8. Moriarty N, Attar N. Clenbuterol-Induced Myocarditis: A Case Report. Eur J Case Rep Intern Med. 2020. PMID: 32908823
  9. Daubert GP, Mabasa VH, Leung VW, Aaron C. Acute clenbuterol overdose resulting in supraventricular tachycardia and atrial fibrillation. J Med Toxicol. 2007. PMID: 18072161
  10. Zeman RJ, et al. Clenbuterol, a beta2-agonist, retards wasting and loss of contractility in irradiated dystrophic mice. Muscle Nerve. 1994

Disclaimer

StackItSmart is an independent harm-reduction reference. The content above is compiled from peer-reviewed literature and is not medical advice, not an endorsement, and not a recommendation to use Clenbuterol. Performance-enhancing compounds carry legal, endocrine, cardiovascular, and hepatic risks. Consult a licensed clinician before any decision. StackItSmart does not provide sourcing, procurement, or dosing prescriptions.

Skip to main content